Abstract
The economic, social and emotional impact of Alzheimer's dementia is increasing dramatically as greater numbers live to advanced ages. The dearth of effective therapies has led to innovative approaches to treat the disease. This review summarizes the rationale, progress and setbacks regarding the use of antibody-based therapies to treat Alzheimer's disease and discusses future directions for this approach in Alzheimer's and other disorders.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Alzheimer Disease / immunology
-
Alzheimer Disease / therapy*
-
Alzheimer Vaccines*
-
Amyloid beta-Peptides / blood
-
Amyloid beta-Peptides / immunology*
-
Animals
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibody Specificity
-
Antigen-Antibody Complex / blood
-
Antigen-Antibody Reactions
-
Cerebral Hemorrhage / etiology
-
Clinical Trials as Topic
-
Disease Progression
-
Epitopes / immunology
-
Humans
-
Immunization, Passive* / adverse effects
-
Mice
-
Mice, Transgenic
-
Microglia / physiology
-
Peptide Fragments / immunology
-
Self Tolerance
-
Vaccination
Substances
-
Alzheimer Vaccines
-
Amyloid beta-Peptides
-
Antibodies, Monoclonal
-
Antigen-Antibody Complex
-
Epitopes
-
Peptide Fragments